



**World Health  
Organization**

INN Working Document 12.306 rev.

ENGLISH ONLY  
07/06/2012

***Pre-stems:  
Suffixes used in the selection of INN  
June 2012***

***Programme on International Nonproprietary Names (INN)***

***Quality Assurance and Safety: Medicines (QSM)***

***World Health Organization,  
Geneva***

© World Health Organization (2012) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

<i>stem</i>	<i>definition</i>
-suffix	
-infix-	
<b>In bold:</b>	new pre-stems selected during the last Consultation.
<b><u>In bold underlined:</u></b>	New stems selected during the last Consultation
<hr/>	
-algron	$\alpha_1$ -adrenoreceptor agonists
-ampator	amino-hydroxymethyl-isoxazole-propionic acid (AMPA) receptor modulators
-ast	<i>antiasthmatics, antiallergics, not acting primarily as antihistaminics</i>
-tegr-	integrin antagonists
-axomab	see <i>mab</i>
-berel	beta estrogen receptor agonists
-buvir	see <i>vir</i>
-camra	intracellular adhesion molecule, ICAM-1 derivatives
-casan	caspase (interleukin-1b) converting enzyme inhibitors
-caserin	serotonin receptor agonists (mostly 5-HT <sub>2</sub> )
-catib	cathepsin inhibitors
-ciclib	cyclin dependant kinase inhibitors
-ciclosporin	ciclosporin derivatives
-codar	see <i>dar</i>
-cridar	see <i>dar</i>
<i>dar</i>	<i>drugs used in multidrug resistance</i>
-cri-	acridinecarboxamide derivatives
-co-	pipecolate derivatives
-spo-	ciclosporin D derivatives
-degib	SMO receptor antagonists

<i>-depsin</i>	depsipeptide derivatives
<i>-domide</i>	antineoplastics, thalidomide derivatives
<i>-ectedin</i>	ecteinarescin derivatives
<i>-estrant</i>	estrogen antagonists
<i>-farnib</i>	farnesyl transferase inhibitors
<i>-fibatide</i>	see <i>tide</i>
<i>-fulven</i>	antineoplastic, acylfulven derivatives
<i>-gacestat</i>	see <i>-stat</i>
<i>-ganan</i>	antimicrobial, bactericidal permeability increasing polypeptides
<i>-gapil</i>	neuronal apoptosis inhibitors, GAPDH
<i>-imepodib</i>	inosine monophosphate dehydrogenase inhibitors
<i>-imidar</i>	see <i>dar</i>
<i>-isant</i>	histamine H <sub>3</sub> receptor antagonists
<i>-kalner</i>	openers of calcium-activated (maxi-K) K <sup>+</sup> -channels
<i>-leptin(e)</i>	leptin derivatives
<i>-lisib</i>	phosphatidylinositol 3-kinase inhibitors, antineoplastics
<i>-lutamide</i>	non-steroid antiandrogens
<i>mab</i>	<i>monoclonal antibodies</i>
<i>-axo-</i>	rat-murine hybrid antibodies
<i>-moren</i>	non-peptidic growth hormone secretagogues
<b><i>-nepag</i></b>	<b>prostaglandins receptors agonists, non-prostanoids</b>
<i>-nesib</i>	kinesin inhibitors
<i>-neurin</i>	neurotrophins
<i>nil</i>	<i>benzodiazepine receptor antagonists/agonists</i>

<i>-punil</i>	mitochondrial benzodiazepine receptor (MBR)- selective agonists also partial or inverse (purine derivatives)
<i>-orexant</i>	<b>orexin receptor antagonists</b>
<i>-osuran</i>	urotensin receptor antagonists
<i>-otilate</i>	hepatoprotectants, diisopropyl-1,3-dithiol-malonate derivatives
<i>-patril/-patrilat</i>	see <i>tril/trilat</i>
<i>-paxar</i>	protease activated receptor type 1 (PAR1) antagonists
<i>peg-/pegol</i>	pegylated compounds (covalent attachment of macrogol (poly(ethylene glycol)) polymer)
<i>-piprant</i>	<b>prostaglandins receptors antagonists, non-prostanoids</b>
<i>-plasimin</i>	inhibitors of plasminogen activator inhibitors-type 1 (PAI-1)
<i>-prazan</i>	proton pump inhibitors, not depended on acid activation
<i>-prinin</i>	nootropic agents, purine derivatives
<i>-punil</i>	see <i>nil</i>
<i>-rafenib</i>	Raf kinase inhibitors
<i>-rixin</i>	chemokine CXCR receptors antagonists
<i>-siban</i>	oxytocin antagonists
<i>-spodar</i>	see <i>dar</i>
<i>-stat/-stat</i>	<i>enzymes inhibitors</i>
<i>-statat</i>	<i>gamma-secretase inhibitors</i>

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28471](https://www.yunbaogao.cn/report/index/report?reportId=5_28471)

